Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study.
Khalaf KridinNoor MruwatKyle T AmberRalf J LudwigPublished in: The British journal of dermatology (2023)
Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis, and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even one year following therapy. No signal for elevated risk of tuberculosis, hepatitis B virus reactivation, pneumocystis jiroveci pneumonia, and progressive multifocal leukoencephalopathy.
Keyphrases
- hepatitis b virus
- diffuse large b cell lymphoma
- sars cov
- newly diagnosed
- ejection fraction
- mycobacterium tuberculosis
- multiple sclerosis
- hodgkin lymphoma
- chronic lymphocytic leukemia
- stem cells
- emergency department
- prognostic factors
- intensive care unit
- liver failure
- hepatitis c virus
- respiratory failure
- replacement therapy
- acute respiratory distress syndrome
- electronic health record